Rationale: Erlotinib, an antineoplastic agent, is indicated for the treatment of patients with advanced nonsmall cell lung cancer. Most common adverse events are manageable, although more severe ones require dose reduction or discontinuation of erlotinib treatment.
Introduction
Erlotinib (Tarceva; Genetech Roche, Basel, Switzerland) is an antineoplastic agent indicated for the treatment of patients with metastatic nonsmall cell lung whose tumors show epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. EGFR is a transmembrane tyrosine kinase (TK) receptor that is frequently expressed in many epithelial tumors, and the aberrant signal through this receptor is associated with cellular neoplastic proliferation, resistance to apoptosis and angiogenesis, thus playing an important role in controlling cellular growth and differentiation. [1] Erlotinib is first-generation quinazoline derivative that selectively and reversibly inhibits the TK activity of EGFR. As a small molecule, it exerts its action intracellularly, [2] while monoclonal antibodies against EGFR act at the membrane extracellular binding site. [1] It is known that EGFR is expressed on the surface of cells in tissues throughout the body, including the skin, hair follicles, and ocular surface epithelia. [3, 4] Although EGFR TK inhibitors show a generally predictable and manageable toxicity, being acneiform rash and diarrhea, the most common adverse events, several ocular side effects have been published, [5] [6] [7] [8] from some case reports describing mild discomfort to others showing severe corneal ulcers refractory to medical or surgical treatments. [9] Anti-EGFR treatment discontinuation, [10] or its dose reduction, [11] is considered to be the only option in these cases. Here, we report a case of severe corneal melting successfully treated with plasma rich in growth factors (PRGF-Endoret; BTI Biotechnology Institute, Vitoria-Gasteiz, Spain) without definitive erlotinib discontinuation.
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A 76-year-old, Caucasian, retired woman, diagnosed with cT2a N0 M1c (stage IVB) lung cancer harboring an EGFR 19 exon deletion, was referred to our practice due to progressive vision loss in her left eye. She had previously received whole brain radiotherapy for multiple brain secondary lesions and at the time of visit, she was in her second month under first-line erlotinib 150 mg once a day (QD), having experienced partial response to the treatment. Her best corrected visual acuity was 20/200 in the left eye and the stilt-lamp examination showed interstitial keratitis and subepithelial fibrosis (Fig. 1A) . Her right eye was normal with 20/20 vision. The rest of the examination was normal in both eyes and nonpreservative lubricant, HyloComod eye-drops (Brill Pharma, Barcelona, Spain) and Thealoz Duo gel (Laboratoires Thea, Clermont, France), with low-dose corticoid topical therapy was initiated.
The evolution in the left eye resulted torpid and a persistent corneal defect appeared 11 months later (Fig. 1B) . Topical antibiotics, such as moxifloxacin (Vigamox, Alcon, Switzerland) and tobramycin (Tobrex, Alcon, Switzerland), were added 4 times daily, and Cacicol (Laboratoires Thea, Clermont, France), a heparan sulfate analog that promotes epithelialization, [12] was added 1 eye-drop every 48 hours for a total of 6 doses. The corneal defect continued to deteriorate showing severe stromal thinning, so topical corticoid was discontinued and PRGFEndoret eye-drops were added, 4 times daily. Temporary discontinuation of erlotinib treatment was indicated, while surgical options were dismissed because of the poor performance status of the patient. Despite this, the corneal ulcer continued to worsen with peripheral corneal neovascularization 360°, important stromal thinning, corneal edema, and profuse inflammation of the ocular surface (Fig. 1C) . Assessing the risk to benefit ratio for the patient per her performance status, after 2 weeks of treatment discontinuation, it was decided to reintroduce erlotinib (at a lower dose of 100 mg QD) and reinstate therapy with topical corticoids to control the inflammation of the ocular surface, maintaining the rest of the eye treatment with topical antibiotics and PRGF. Fifteen days later, a significant improvement was observed (Fig. 1D) . A contact lens was tried but afterwards removed due to intolerance caused by the ectasia with descemetocele that prevented a good adaptation. In subsequent visits, corticoids were tapered and eventually suspended, while corneal integrity was maintained using conservative medical treatment with the same lubricants and PRGF for over a year of follow-up (Fig. 2) .
Conclusion
The binding of the epidermal growth factor (EGF) activates its receptor through phosphorylation, stimulating the proliferation of corneal epithelial cells. [13] This signaling pathway is considered paramount to the healing of corneal epithelial defects and animal tests have shown that the administration of systemic EGFR inhibitors delay corneal healing. [13] There are reported cases of ocular perforations that have required keratoplasty, [9] corneal melting treated with autologous serum, [10] and epithelial defects that have persisted despite topical treatment [8] in patients treated with standard doses of erlotinib. Treatment with autologous PRGF can theoretically decrease the effect of high molecular weight EGFR inhibitors, as they compete for extracellular EGFR binding sites. However, low molecular weight inhibitors act intracellularly, inhibit the intracellular phosphorylation of EGFR, and would not affect the inhibition of enzymatic activity, so erlotinib treatment should be suspended in order to see some improvement or even to achieve spontaneous healing. [11] In our case, no relevant changes were observed when treatment with erlotinib was temporarily discontinued for 2 weeks, despite that this drug has a half-life of about 36 hours. [2] Even when erlotinib treatment was resumed, our patient showed anatomical and symptomatic improvement under treatment with topical PRGF. After 1 year of follow-up, corneal integrity was maintained avoiding perforation and an increased corneal thickness in the periphery of the descemetocele was observed (Fig. 2) , as well as less epithelial damage. To the best of our knowledge, this is the first reported case in which PRGF have significantly contributed to corneal healing in a patient under erlotinib treatment. Some of the growth factors present in PRGF, such as EGF, hepatocyte growth factor (HGF), and keratinocytes growth factor (KGF), have been described as key regulators in corneal wound healing, employing different signaling pathways in charge of stimulating the proliferation of epithelial cells. In the corneal stroma, PRGF is able to mediate these processes thanks to other factors such as transforming growth factor (TGF), plateletderived growth factor (PDGF), and fibroblast growth factor (FGF). [14] The different signaling pathways through which the different growth factors operate, other than EGFR, may explain the clinical improvement in our patient despite continuing treatment with erlotinib. Corneal injury triggers the infiltration of immune cells into the cornea from the limbal vessels, necessary for proper wound healing, but too many immune cells accumulation also results in delayed wound closure, demonstrating the delicate balance of inflammatory events needed during corneal healing. [15] In this case presented, the corneal damage improvement with the treatment provided allowed the patient to further maintain erlotinib treatment continuing to systemically benefit from the drug for more than a year after the adverse event was diagnosed.
Considering the poor results of conventional treatment, both medical and surgical, we believe that management of the inflammation of the ocular surface together with the stimulation of the healing processes through regenerative therapy, such as PRGF, can be an option worth considering in these cases of poor prognosis. 
